top of page

Dr. Susanne Petri Joins NDR Scientific Group

Updated: May 20, 2022

NDR Inc is pleased to announce that Dr. Susanne Petri has joined our scientific group. Dr. Petri is an Associate Professor in the Department of Neurology at the Hannover Medical School in Hannover, Germany, and has published over 10 important papers in the ALS field in the past 5 years.


Her studies center on using patient-derived induced pluripotent stem cells, iPSC, and using these cells to analyze therapeutics for ALS patients. She published her work on the roles of ALS-associated toxic proteins in cell culture and mouse models and she studied the role of altered calcium dynamics and glutamate receptors in iPSCs from patients with ALS.


She published several genetic studies as well as clinical trials testing the safety and effectiveness of levosimendan in ALS patients. She studies gene variants in ALS patients. She brings her expertise in culturing induced motor neurons and therapeutics to our discovery program.


NDR funded a two-year program that will investigate the therapeutic potential of drug interventions on the microglia in ALS mouse models.

19 views0 comments

Recent Posts

See All

Thymosin in the treatment of lung cancer

A new paper authored by Liu and Lu in the Frontiers in Immunology reports the Mechanism and clinical application of thymosin in the treatment of lung cancer. Thymosin is a mixture of peptides obtained

MOLECULAR MECHANISMS OF REDOX REGULATION IN INFLAMMATION

We are hopeful that TVALA will reduce p53 expression in people with ALS. There are two recent publications that give us hope. The first paper is by Maor-Nof et. al. (2022), found in Cell. The found

TVALA Fortune Journal

Pharmacological Characterization of FC-12738: A Novel Retro-Inverso Pentapeptide for Treating Neuroinflammation

bottom of page